N/A N=655 Aortoiliac Stenosis in Kidney Transplantation
Aorto-Iliac Arterial Stenosis · Peripheral Arterial Disease · Kidney Transplant Failure
Primary: Patient Survival — 322; 48; 6 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=141 Iliac Artery Treatment With The Invatec Scuba™ Cobalt Chromium Stent (INTENSE)
Peripheral Artery Disease
Primary: Composite of Major Adverse Events (MAE) Defined as the Occurrence of In-hospital Myocardial Infarction (MI) or Target Segment Revascularization, Target Limb Loss, or…
Phase 3 N=153 Trial to Evaluate the Safety & Efficacy of the Omnilink Elite™ Peripheral Balloon-Expandable Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery
Peripheral Vascular Disease
Primary: Major Adverse Event (MAE) — 5.4 percentage of participants
Phase 3 N=151 Trial to Evaluate the Safety & Efficacy of the Absolute Pro™ Peripheral Self-Expanding Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery.
Peripheral Vascular Disease
Primary: Major Adverse Event (MAE) Rate — 6.1 percentage of participants
N/A N=134 A Study of the Gore VIABAHN BX for Treatment of Occlusive Disease in the Iliac Arteries.
Peripheral Arterial Disease
Primary: Composite of Major Adverse Events (MAEs) — 2.3 percentage of subjects experiencing MAE — p=<0.001
N/A N=155 BARD® Study of LIFESTREAM™ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease
Peripheral Artery Disease · Peripheral Vascular Disease · Arterial Occlusive Disease
Primary: Number of Participants With Device and/or Procedure-Related Death or Myocardial Infarction (MI) Through 30 Days, or Any Target Lesion Revascularization (TLR), Target…
N/A N=123 The ACTIVE (Use of the Assurant® Cobalt Iliac Stent System in the Treatment of Iliac Vessel Disease) Study
Peripheral Vascular Disease
Primary: Major Adverse Events (MAE), Measured as Device and/or Procedure Related Death, Target Limb Loss and/or Clinically Driven Target Lesion Revascularization (TLR) or Target…
N/A N=194 Endurant Bifurcated and Aorto-Uni-Iliac (AUI) Stent Graft System
Abdominal Aortic Aneurysms
Primary: Primary Safety Endpoint (Freedom From MAEs Within 30 Days of Index Procedure) — 88.6; 96.0 percentage of participants
N/A N=165 Atrium iCAST Iliac Stent Pivotal Study
Peripheral Vascular Disease
Primary: Percentage of ITT Population Experiencing Death Within 30 Days, Target Site Revascularization or Restenosis — 8.1 Percentage of subjects — p=0.005
N/A N=40 PRESERVE-Zenith® Branch Endovascular Graft-Iliac Bifurcation Clinical Study
Aortoiliac Aneurysms · Iliac Aneurysms
Primary: Number of Patients With Freedom From Patency-related Intervention Defined as a Secondary Intervention to Treat a > 60 % Stenosis of the Internal Iliac Artery Associated…
N/A N=51 Impact of Grafts and Endografts for Abdominal Aneurysms on Arterial Stiffness.
Aortic Aneurysm, Abdominal
Primary: Aix@75 — 31.8; 32.5 percentage
N/A N=75 VISIBILITY™ Iliac Study
Peripheral Arterial Disease · Claudication
Primary: Major Adverse Event Rate at 9 Months — 4.0 percentage of participants
N/A N=401 Endovascular Exclusion of Abdominal Aortic Aneurysms in High Risk Patients
Abdominal Aortic Aneurysm · Iliac Aneurysm · Internal Iliac Aneurysm
Primary: Freedom From Aneurysm Rupture — 0 Participants
Phase 3 N=947 Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions
Atherosclerosis · Cardiovascular Diseases · Hypertension, Renovascular
Primary: Composite Endpoint: Death From Cardiovascular or Renal Causes, Stroke, Myocardial Infarction, Hospitalization for CHF, Progressive Renal Insufficiency, or Permanent…
N/A N=50 The Complete® Self-Expanding Stent and Stent Delivery System Registry
Peripheral Vascular Disease
Primary: The Number of Participants With Major Adverse Events (MAE) — 0 participants
N/A N=151 Evaluation of Safety and Efficacy of the S.M.A.R.T. RADIANZ™ Vascular Stent System in the Treatment of Iliac and Femoropopliteal Lesions Via Transradial Access
Peripheral Arterial Disease
Primary: Occurrence Rate of Radial Access Site Complications (Primary Safety Outcome) — 0 Participants
N/A N=146 Prevalence of Renal Artery Stenosis in Patients Referred for Cardiac Catheterization
Renal Artery Stenosis
Primary: Prevalence of Renal Artery Stenosis (RAS)
N/A N=171 Multi-center Study for Stent Graft System for Peripheral Artery
Peripheral Arterial Disease
Primary: Primary Assisted Patency — 91 Participants — p=<0.0001
N/A N=121 Revolution™ Peripheral Atherectomy System for Lower Extremity Peripheral Arterial Revascularization
Peripheral Artery Disease
Primary: Safety Endpoint: Number of Participants With Freedom From Major Adverse Events — 110 Participants
Phase 3 N=125 EPIC Nitinol Stent System in the Treatment of Atherosclerotic Lesions in Iliac Arteries
Iliac Artery Stenosis
Primary: Device- and/or Procedure-related Major Adverse Events (MAE) — 3.4 percentage of participants — p=<0.0001
Phase 2 N=82 Covered CP Stents for the Prevention or Treatment of Aortic Wall Injury Associated With Coarctation of the Aorta
Aortic Coarctation
Primary: Study Participants With Grade 4 or 5 in Degree of Aortic Wall Injury (AWI) and/or Aortic Arch Obstruction Without Clinical Worsening — 55 participants
N/A N=29 JetStream (JS) Atherectomy in Femoropopliteal In-Stent Restenotic Lesions
Restenosis · Peripheral Vascular Disease
Primary: Acute Procedural Success — 29 limbs
Phase 4 N=148 GORE VIABAHN ENDOPROSTHESIS Peripheral Vascular Disease Study
Peripheral Vascular Diseases
Primary: Efficacy: Primary Patency at Three Years — 24.2; 25.9 percentage of subjects
N/A N=57 Stenting of the Superficial Femoral and/or Proximal Popliteal Artery Project
Atherosclerosis of Native Arteries of the Extremities
Primary: Primary Patency — 94.4 percentage of lesions
N/A N=200 ABRE Clinical Study of the Abre Venous Self-expanding Stent System
Iliofemoral Venous Obstruction
Primary: Primary Patency — 162 Participants — p=<0.0001
N/A N=75 DURABILITY™ Iliac Study
Peripheral Arterial Disease · Claudication
Primary: Major Adverse Event Rate — 1.3 percentage of participants
N/A N=70 Belgian Trial Investigating the LifeStream Stent in Complex TASC C and D Iliac Lesions
Peripheral Arterial Disease
Primary: Primary Patency Rate Before Completion of the 12-month Follow-up Period. — 3 participants
N/A N=75 Expanding Patient Applicability With Polymer Sealing Ovation Alto Stent Graft Investigational Device Exemption (IDE) Study
Aortic Aneurysm, Abdominal
Primary: Number of Subjects With Treatment Success — 58 Participants
N/A N=162 Venous Stent for the Iliofemoral Vein Investigational Clinical Trial Using the DUO Venous Stent System
May-Thurner Syndrome · Deep Vein Thrombosis · Chronic Venous Insufficiency
Primary: Safety - Number of Participants Free From Major Adverse Events (MAEs) at 30 Days — 157 Participants
N/A N=68 Renal Stent Placement for the Treatment of Renal Artery Stenosis in Patients With Resistant Hypertension
Renal Artery Stenosis · Hypertension, Renovascular
Primary: Primary Patency — 66 Subject-lesions — p=<.0001